ReviewLeukemia2008
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Review in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Guideline
- The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.Blood advances · 2022Trial
- A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.Annals of hematology · 2018Trial
- Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- Mathematical modeling ofProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.International journal of hematology · 2026Article
- Practical guide for the diagnosis and treatment of localized and generalized cutaneous pruritus (chronic itch with no underlying pruritic dermatosis).The Journal of dermatology · 2025Review
- Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2Global medical genetics · 2024Article
- JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study.Blood advances · 2023Article
- Clinical Impact ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.International journal of molecular sciences · 2023Review
- Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.Current treatment options in oncology · 2023Review
- A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High LevelDiagnostics (Basel, Switzerland) · 2023Article
- International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.Virchows Archiv : an international journal of pathology · 2023Review
- Bilateral adrenal and pulmonary haemorrhages as an initial presentation of polycythaemia vera.BMJ case reports · 2022Article
- Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.Blood advances · 2022Article
- Genetic Background of Polycythemia Vera.Genes · 2022Review
- The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.Turkish journal of medical sciences · 2022Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) as well as in a much smaller percentage of those with other MPNs. The mechanism(s) behind this one allele-multiple phenotypes phenomenon has not been fully elucidated. The issue is further confounded by the presence of marked variation in JAK2V617F allele burden among mutation-positive patients. In the current communication, we discuss potential mechanisms for phenotypic diversity among JAK2V617F-positive MPNs as well as review the current literature in regard to genotype-phenotype correlations (that is clinical correlates and prognostic significance) in the context of both the presence or absence of the mutation (ET and PMF) and its allele burden (PV, ET and PMF).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.